Inna Goldfarb
- Pharmacology top 2%
- Immunology
- Radiology, Nuclear Medicine and Imaging top 10%
- Molecular Biology
- Oncology
- Co-authors
- Harry V. GelboinPaolo CasaliNagaradona HarindranathAbner Louis NotkinsKristopher W. KrauszFrank J. GonzalezKenneth R. KorzekwaJeroen Buters
- Topics
- Pharmacogenetics and Drug Metabolism (7 papers)Monoclonal and Polyclonal Antibodies Research (4 papers)Carcinogens and Genotoxicity Assessment (3 papers)
- Cited by
- PharmacologyImmunologyVirology
- Journals
- The Journal of Experimental MedicineThe Journal of ImmunologyArchives of Biochemistry and Biophysics
- Partner nations
- United States
In The Last Decade
Inna Goldfarb
13 papers receiving 487 citations
Peers
Comparison fields: 5 of 64
- Pharmacology 191
- Immunology 172
- Radiology, Nuclear Medicine and Imaging 137
- Molecular Biology 124
- Oncology 110
Countries citing papers authored by Inna Goldfarb
This map shows the geographic impact of Inna Goldfarb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inna Goldfarb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inna Goldfarb more than expected).
Fields of papers citing papers by Inna Goldfarb
This network shows the impact of papers produced by Inna Goldfarb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inna Goldfarb. The network helps show where Inna Goldfarb may publish in the future.
Co-authorship network of co-authors of Inna Goldfarb
This figure shows the co-authorship network connecting the top 25 collaborators of Inna Goldfarb. A scholar is included among the top collaborators of Inna Goldfarb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inna Goldfarb. Inna Goldfarb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. | 26 |
| 2 | 5 | |
| 3 | 55 | |
| 4 | 4 | |
| 5 | 24 | |
| 6 | 47 | |
| 7 | 45 | |
| 8 | 22 | |
| 9 | 46 | |
| 10 | 4 | |
| 11 | 107 | |
| 12 | 16 | |
| 13 | 97 |
About Inna Goldfarb
Inna Goldfarb is a scholar working on Pharmacology, Cancer Research and Immunology, having authored 13 papers that have together received 498 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Carcinogens and Genotoxicity Assessment (3 papers). The work is most often cited by research in Pharmacology (191 citations), Immunology (172 citations) and Virology (29 citations). Inna Goldfarb has collaborated with scholars based in United States. Frequent co-authors include Harry V. Gelboin, Paolo Casali, Nagaradona Harindranath, Abner Louis Notkins, Kristopher W. Krausz, Frank J. Gonzalez, Kenneth R. Korzekwa, Jeroen Buters, Magang Shou and Hideyuki Ikematsu. Their work appears in journals such as The Journal of Experimental Medicine, The Journal of Immunology and Archives of Biochemistry and Biophysics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.